Purple Biotech (PPBT) Cash & Current Investments (2017 - 2021)

Purple Biotech (PPBT) has disclosed Cash & Current Investments for 5 consecutive years, with $47.2 million as the latest value for Q4 2021.

  • On a quarterly basis, Cash & Current Investments fell 18.35% to $47.2 million in Q4 2021 year-over-year; TTM through Dec 2021 was $47.2 million, a 18.35% decrease, with the full-year FY2021 number at $47.2 million, down 18.35% from a year prior.
  • Cash & Current Investments was $47.2 million for Q4 2021 at Purple Biotech, down from $57.8 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $57.8 million in Q4 2020 to a low of $4.4 million in Q4 2019.
  • A 5-year average of $24.7 million and a median of $7.4 million in 2017 define the central range for Cash & Current Investments.
  • Peak YoY movement for Cash & Current Investments: tumbled 34.25% in 2019, then soared 1215.24% in 2020.
  • Purple Biotech's Cash & Current Investments stood at $7.4 million in 2017, then fell by 10.1% to $6.7 million in 2018, then crashed by 34.25% to $4.4 million in 2019, then skyrocketed by 1215.24% to $57.8 million in 2020, then decreased by 18.35% to $47.2 million in 2021.
  • Per Business Quant, the three most recent readings for PPBT's Cash & Current Investments are $47.2 million (Q4 2021), $57.8 million (Q4 2020), and $4.4 million (Q4 2019).